Profile
XAGE VRTX REGN VRNA ARGX ALNY
Company Name Longevity Health Holdings Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $430.43K $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.02K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Rajiv Sarman Shukla Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
XAGE VRTX REGN VRNA ARGX ALNY
Quant Rating Score 2 4 4 1 4 3
Quant Rating Sell Buy Buy Strong Sell Buy Neutral
Trading
XAGE VRTX REGN VRNA ARGX ALNY
Last Close $0.48 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $5.86 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.12 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -91.81 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 300 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
XAGE VRTX REGN VRNA ARGX ALNY
1 Month Return -7.69 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return -80.41 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return -84 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 0 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 0 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 0 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
XAGE VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -266.8 % 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
XAGE VRTX REGN VRNA ARGX ALNY
Asset Growth -97.7 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth 135.23 % 1.16 % - 26.81 %
Revenue Growth - 0.99 % - 22.97 %
Revenue 3 Year - 20.64 % -15.89 % 147.1 %
Revenue 5 Year - 73.64 % - 775.72 %
Revenue 10 Year - 285.02 % - 2487.4 %
EBIT Growth 30.15 % 9.09 % -131.37 % 24.59 %
Net Income Growth 32.87 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share -51.33 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share -51.33 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share -51.33 % 680.22 % -35.51 % 55.09 %
Operating Income Growth 4.19 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) 47.43 % - -143.33 % -107.98 %
Operating 3 Year CFG -252.67 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG -252.67 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG -252.67 % -100 % 40.15 % 97.08 %
EPS Growth 32.43 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth 32.43 % 8.19 % -208.93 % 38.07 %
Book Value Per Share -118.92 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share 84.93 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share 84.93 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share 84.93 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth -70.09 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth 47.62 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
XAGE VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM 54.63 % 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -173.88 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM 141.35 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM 164.97 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 98.33 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 99.84 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM -400.96 % 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -613.44 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM 31.33 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM 0.16 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM 0.65 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM 332.11 % 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM 44.17 % 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -2.2 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -2.21 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 64.39 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM -260.41 % 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.37 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -613.44 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -0.11 36.72 20 -995.27 127.92 195.85
Price To Operating Cash Flows Ratio TTM -0.13 32.86 16.23 -126.33 144.41 162.25
Price Cash Flow Ratio TTM -0.13 32.86 16.23 -126.33 144.41 162.25
Income Statement (TTM)
XAGE VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.34B $0.03B $2.19B $2.25B
Gross Profit $0B $9.49B $12.24B $0.03B $1.96B $1.92B
Gross Profit Ratio 87.37% 86.11% 85.35% 93.89% 89.62% 85.62%
EBITDA $-0.01B $0.49B $5.82B $-0.12B $0.11B $-0.18B
Net Income $-0.01B $-0.54B $4.5B $-0.14B $0.83B $-0.28B
EPS Diluted -0.5 -2.08 41.48 -1.73 12.78 -2.18
Balance Sheet (MRQ)
XAGE VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.71B $0.12B $0.03B $2.59B
Total Liabilities $0.01B $6.12B $9.3B $0.27B $0.7B $4.17B
Total Equity $-0B $16.41B $31.26B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $16.08B $0.02B $1.93B $1.73B
Total Debt $0B $1.75B $2.71B $0.12B $0.04B $2.74B
Total Assets $0B $22.53B $40.56B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
XAGE VRTX REGN VRNA ARGX ALNY
Net Income $-0.01B $-0.54B $4.5B $-0.17B $0.83B $-0.28B
Inventory $-0B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0B $-0.49B $4.98B $-0.12B $-0.08B $-0.01B
Capital Expenditure $0B $-0.3B $-0.9B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.52
AARD Aardvark Therapeutics, Inc. Common Stock 13.425
ABCL AbCellera Biologics Inc. 3.22
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.135
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.475
ABPWW 0.0155
ABSI Absci Corporation 2.76
ABUS Arbutus Biopharma Corporation 4.055
ABVC ABVC BioPharma, Inc. 1.74
ABVX Abivax SA American Depositary Shares 119.9
ACAD ACADIA Pharmaceuticals Inc. 23.225
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.12
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.1
ETFs With Exposure to XAGE
Ticker ETF Name Weight Percentage Price
VXF Vanguard Extended Market Index Fund 0.00001 219.57
IWC iShares Micro-Cap ETF 0.00028 170.76
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00001 165.43
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00001 165.44
VEMPX Vanguard Extended Market Index InstlPlus 0.00001 408.25
Unlock